Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/54375
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAmr, A E-
dc.contributor.authorElsayed, E A-
dc.contributor.authorAl-Omar, M A-
dc.contributor.authorAlmehizia, A A-
dc.contributor.authorAbdel-Mageid, Randa E.-
dc.date.accessioned2020-05-15T08:05:43Z-
dc.date.available2020-05-15T08:05:43Z-
dc.date.issued2020-04-
dc.identifier.issn0975-1084 (Online); 0022-4456 (Print)-
dc.identifier.urihttp://nopr.niscair.res.in/handle/123456789/54375-
dc.description292–296en_US
dc.description.abstractCurrent research aimed at evaluating the in vitro as well as in vivo anticancer activities of a newly synthesized peptide hydrazide; i.e. 4,14-diisopropyl-2,5,13,16-tetraoxo-3,6,12,15-tetraaza-1(3,5)-pyridinacyclohexadecaphane-7-carbohydrazide. The hydrazide was synthesized from methyl 4,14-diisopropyl-2,5,13,16-tetraoxo-3,6,12,15-tetraaza-1(3,5)-pyridinacyclohexadecaphane-7-carboxylate 2 by acting of hydrazine hydrate. It showed significant anticancer effects against different tested cell lines, where cervical, breast, liver, colon, prostate, brain, fibrosarcoma, leukemia and melanoma cell lines were the most affected cell types. The prepared derivative also inhibited VEGF-2 kinase enzyme significantly and exhibited an in vivo tumorigenic effects in mice model.en_US
dc.language.isoen_USen_US
dc.publisherNISCAIR-CSIR, Indiaen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceJSIR Vol.79(04) [April 2020]en_US
dc.subjectAnticanceren_US
dc.subjectSynthesisen_US
dc.subjectPeptidesen_US
dc.subjectHydrazideen_US
dc.subjectMechanism of actionen_US
dc.titleCyclo (Nα-dinicotinoyl)-bis-[(L-valinyl)-L-lysinyl acid hydrazide]: Assessment of its Role in Cancer and Kinase Activity Inhibitionen_US
dc.typeArticleen_US
Appears in Collections:JSIR Vol.79(04) [April 2020]

Files in This Item:
File Description SizeFormat 
JSIR 79(4) 292-296.pdf275.87 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.